The latest international news, analysis and features on the HIV epidemic from Avert. Share your views and expertise with your peers in the comments box below the articles.
The number of men testing positive for HIV fell dramatically in England last year, revealing the remarkable impact of targeted interventions for men who have sex with men.
First known intervention to increase positive attitudes in people newly diagnosed with HIV found to have profound health benefits.
HIV as a risk factor for diabetes has long been controversial, but new evidence shows that people living with HIV have increased diabetes prevalence compared to the general population.
The UK has exceeded UNAIDS Fast-Track targets of getting people on treatment and virally suppressed, but falls behind on reaching those who are undiagnosed.
Phase III trials of the intravenous drug ibalizumab have been found to significantly reduce viral load in people living with HIV who do not respond to existing treatment.
John Hopkins is set to be the first hospital in the USA to conduct an HIV-positive to HIV-positive kidney transplant, and the first in the world to conduct a liver transplant between two HIV-positive people.
As people living with HIV grow older, they have a greater chance of developing certain types of cancers compared to the general population.
A quarter of people living with HIV in the UK are aged over 50, according to recent statistics from Public Health England. While care of HIV-positive people was once the domain of specialist staff, people living with HIV are now living full lives thanks to treatment, and are more often seen by general health services. However, the care needs of older HIV-positive people still require careful consideration, as many primary providers do not have up-to-date knowledge of HIV.
Individuals who choose not to disclose their HIV status are not more likely to suffer from depression or anxiety, have more problems with treatment adherence or worse HIV outcomes, according to a large study presented at the British HIV Association (BHIVA) conference in Brighton last week.
A study that looked at health insurance plans under the new Affordable Care Act (ACA) in the United States has found that people living with HIV (PLHIV) on some plans are paying on average $3000 more than PLHIV on other plans. The findings have sparked concerns that these insurance providers are pricing antiretroviral drugs (ARVs) in the highest bracket within their plans – in what has been called ‘adverse tiering’ – to discourage PLHIV taking up policies.